Allos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T...
05 Outubro 2009 - 8:00AM
Business Wire
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that
FOLOTYN™ (pralatrexate injection) is now available for commercial
sale in the United States. The U.S. Food and Drug Administration
(FDA) granted accelerated approval for FOLOTYN for use as a single
agent for the treatment of patients with relapsed or refractory
peripheral T-cell lymphoma (PTCL) on September 24, 2009. This
indication is based on overall response rate. Clinical benefit such
as improvement in progression free survival or overall survival has
not been demonstrated. For full prescribing information for
FOLOTYN, visit www.folotyn.com. FOLOTYN is the first and only drug
approved by the FDA for this indication and represents a new
therapeutic option for patients with relapsed or refractory
PTCL.
Allos plans to market and sell FOLOTYN in the U.S. through its
commercial organization, which includes 25 sales specialists and
will be increased to approximately 50 in advance of the Company’s
planned full-scale commercial launch in January 2010. FOLOTYN is
now available to U.S. health care providers through their normal
ordering process.
Allos is dedicated to patient access and has established a
patient assistance program named ASAP (Allos Support for Assisting
Patients) to provide reimbursement support. Commencing in October,
more information regarding ASAP will be available by calling the
Hotline at 1-877-ASAP102 (272-7102), Monday to Friday, 8 am to 7 pm
Central Time or by visiting www.getASAPinfo.com.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. FOLOTYN is the first and only
drug approved in the U.S. for the treatment of patients with
relapsed or refractory peripheral T-cell lymphoma. Allos is also
developing FOLOTYN in other potential indications. Allos retains
exclusive worldwide rights to FOLOTYN for all indications. The
Company is headquartered in Westminster, CO. For additional
information, please visit www.allos.com.
Important Safety Information
Warnings and Precautions:
FOLOTYN may suppress bone marrow function, manifested by
thrombocytopenia, neutropenia, and anemia. Monitor blood counts and
omit or modify dose for hematologic toxicities.
Mucositis may occur. If ≥ Grade 2 mucositis is observed, omit or
modify dose.
Patients should be instructed to take folic acid (1.0 -1.25 mg
orally on a daily basis) and receive vitamin B12 (1 mg
intramuscularly every 8-10 weeks) to potentially reduce
treatment-related hematological toxicity and mucositis.
FOLOTYN can cause fetal harm. Women should avoid becoming
pregnant while being treated with FOLOTYN, and pregnant women
should be informed of the potential harm to the fetus.
Use caution and monitor patients when administering FOLOTYN to
patients with moderate to severe renal function impairment.
Elevated liver function test abnormalities may occur and require
monitoring. If liver function test abnormalities are ≥ Grade 3,
omit or modify dose.
Adverse Reactions:
The most common adverse reactions observed in PROPEL were
mucositis (70%), thrombocytopenia (41%), nausea (40%), and fatigue
(36%). The most common serious adverse events (>3%),
regardless of causality, were pyrexia, mucositis, sepsis, febrile
neutropenia, dehydration, dyspnea and thrombocytopenia. Forty-four
percent of patients experienced a serious adverse event while on
study or within 30 days after their last dose of FOLOTYN.
Twenty-three percent of patients discontinued treatment due to
adverse reactions.
Drug Interactions:
Co-administration of drugs subject to renal clearance (e.g.,
probenecid, NSAIDs, and trimethoprim/sulfamethaxazole) may result
in delayed renal clearance.
Use in Specific Patient Population:
Nursing mothers should be advised to discontinue nursing or the
drug, taking into consideration the importance of the drug to the
mother.
For additional important safety information, please see the full
prescribing information for
FOLOTYN at www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include the Company’s statements regarding the potential
for FOLOTYN to offer an important new treatment option for patients
with relapsed or refractory PTCL; the Company’s anticipated
timeline and size of its sales force for its planned full-scale
commercial launch of FOLOTYN; and other statements that are other
than statements of historical facts. In some cases, you can
identify forward-looking statements by terminology such as “may,”
“will,” “should,” “expects,” “intends,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “potential,”
“continue,” and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement
is not forward-looking. Such forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements. Important
factors that may cause actual results to differ materially include,
but are not limited to, the risks and uncertainties associated with
developing adequate sales, marketing and distribution capabilities;
the acceptance of FOLOTYN in the marketplace; the status of
reimbursement from third party payers; the Company’s dependence on
third party manufacturers; the Company’s compliance with applicable
regulatory requirements, including the healthcare fraud and abuse
laws and the Company’s post-marketing requirements; and the
Company’s access to capital to support its future operations,
including product development and commercialization plans for
FOLOTYN. Additional information concerning these and other factors
that may cause actual results to differ materially from those
anticipated in the forward-looking statements is contained in the
"Risk Factors" section of the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2009, and in the Company's
other periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Note: The Allos logo and FOLOTYN name are trademarks of Allos
Therapeutics, Inc.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024